Publications – KalVista Pharmaceuticals

Showing 7 out of 7

Factor XIIa Inhibition Protects Against VEGF-induced Neuroretinal Dysfunction in Mice

Clermont A, Murugesan N, Feener EP
ARVO 2024

Oral FXIIa inhibitor KV998086 suppresses FXIIa and single chain FXII mediated kallikrein kinin system activation

Clermont AC, Murugesan N, Edwards HJ, Lee DK, Bayliss NP, Duckworth EJ, Pethen SJ, Hampton SL, Gailani D, Feener EP

PB0536: Oral Factor XIIa inhibitor KV998086 protects against FeCl3 induced thrombosis in mice.

Clermont A, Pinckney F, Hill M, Hampton SL, Feener EP

Novel Oral Small Molecule FXIIa Inhibitor Blocks Contact System Activation In Vivo

Allen C Clermont, Daniel Lee, Nivetha Murugesan, Hannah J Edwards, Stephen J Pethen, Edward J Duckworth, Sally L Hampton and Edward P Feener

Oral factor XIIa inhibition blocks angiotensin converting enzyme inhibitor induced angioedema in mouse

Clermont AC, Murugesan N, Feener EP

Oral FXIIa inhibitor KV998086 suppresses FXII zymogen mediated kallikrein kinin system activation

Murugesan N, Lee DK, Duckworth EJ, Smith SA, Clermont AC, Hampton SL, Feener EP

Selective Factor XIIa inhibitor KV998083 protects mice against captopril induced vascular leakage and cleavage of high molecular weight kininogen

Clermont AC, Murugesan N, Edwards HJ, Whitney SA, Pethen SJ, Duckworth EJ, Hampton SL, Feener EP

About